NCT01174199 2022-10-03
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
Clinical Trials
13 trialsNCT01083368 2019-08-21
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01026623 2019-06-17
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01206036 2016-01-27
CEPTAS
Central European Society for Anticancer Drug Research
Phase 1/2 Completed
NCT01020305 2014-10-13
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Stanford University
Phase 1/2 Terminated
NCT00919035 2014-06-30
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Oncology Specialists, S.C.
Phase 2 Completed
NCT00887640 2014-02-26
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Duke University
Phase 2 Terminated
NCT00012142 2013-06-24
CCI-779 in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00071968 2013-01-08
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00512668 2013-01-07
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00235794 2007-12-27
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Wyeth is now a wholly owned subsidiary of Pfizer
Phase NA Completed